Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04613453

Organisation Name: Yale University

Overal Status: Not yet recruiting

Start Date: August 2021

Last Update: July 20, 2021

Lead Sponsor: Yale University

Brief Summary: The purpose of this study is to determine if intravenous ketamine reduces suicidal thinking compared to an active placebo (midazolam) in adolescents who have treatment resistant depression and a recent history of a suicide event (defined as a suicide attempt, emergency room evaluation for suicidal thinking, or a transition to inpatient care for suicidality in the past 120 days).

The primary objective of this study is to determine whether ketamine reduces suicidal ideation (as measured via the C-SSRS, recent ideation scale) relative to an active control, midazolam, 48-hours after first administration in adolescents with TRD at high suicide risk.

Conditions:
  • Adolescent Suicide


Total execution time in seconds: 0.52918195724487